

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Tafluprost Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
120 Moorgate  
EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Not a hazardous substance or mixture.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210 Safety data sheet available on request.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Tafluprost	209860-87-7	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 1; H370 (Lungs, Cardio-vascular system) STOT RE 1; H372 (Lungs, Cardio-vascular system) Aquatic Chronic 4; H413	$\geq 0.0002$ - $< 0.0025$
Substances with a workplace exposure limit :			
Glycerine	56-81-5 200-289-5		$\geq 1$ - $< 10$

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- |                            |   |
|----------------------------|---|
| Protection of first-aiders | : No special precautions are necessary for first aid responders.  |
| If inhaled                 | : If inhaled, remove to fresh air.<br>Get medical attention if symptoms occur.  |
| In case of skin contact    | : Wash with water and soap as a precaution.<br>Get medical attention if symptoms occur.                                   |
| In case of eye contact     | : Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.                    |
| If swallowed               | : If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water. |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environ-

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

ment Agency (emergency telephone number 0800 807060).

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  
Local/Total ventilation : Use only with adequate ventilation.  
Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.  
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.  
Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version 6.1      Revision Date: 14.04.2025      SDS Number: 9372636-00010      Date of last issue: 03.12.2024  
Date of first issue: 27.08.2021

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m <sup>3</sup>	GB EH40
Tafluprost	209860-87-7	TWA	0.002 µg/m <sup>3</sup> (OEB 5)	Internal
Further information: Skin, Eye				
		Wipe limit	0.02 µg/100 cm <sup>2</sup>	Internal

##### Derived No Effect Level (DNEL)

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m <sup>3</sup>
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m <sup>3</sup>

##### Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3.3 mg/kg dry weight (d.w.)
	Marine sediment	0.33 mg/kg dry weight (d.w.)
	Soil	0.141 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

##### Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to BS EN 14387
Filter type	:	Organic vapour type (A)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance	:	Aqueous solution
Colour	:	clear
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Molecular weight	:	No data available
Particle size	:	No data available

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

### 10.5 Incompatible materials

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Tafluprost:

Acute oral toxicity : LD50 (Rat): 665 mg/kg  
LD50 (Rat): > 100 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg  
Application Route: Intravenous  
Target Organs: Cardio-vascular system

##### Glycerine:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Glycerine:

Species : Rabbit  
Result : No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Tafluprost:

Species : Monkey  
Result : No eye irritation



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

### Glycerine:

Species	:	Rabbit
Result	:	No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

### Components:

#### Tafluprost:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Tafluprost:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosome aberration test in vitro Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

### Glycerine:

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative  Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosome aberration test in vitro Result: negative  Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negative
-----------------------	---	--

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

### Carcinogenicity

Not classified based on available information.

### Components:

#### Tafluprost:

Species	:	Rat
Application Route	:	Subcutaneous
Exposure time	:	24 Months
Result	:	negative

Species	:	Mouse
Application Route	:	Subcutaneous
Exposure time	:	18 Months
Result	:	negative

#### Glycerine:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Tafluprost:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Intravenous injection Fertility: NOAEL: 100 µg/kg Result: No effects on fertility
----------------------	---	--

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Intravenous injection Developmental Toxicity: LOAEL: 10 µg/kg Result: Malformations were observed., Reduced foetal weight
-------------------------------	---	--

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 3 µg/kg

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 0.03 µg/kg  
Result: Malformations were observed.

Test Type: Embryo-foetal development

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.01 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### **Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### **STOT - single exposure**

Not classified based on available information.

### **Components:**

#### **Tafluprost:**

Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs.

### **STOT - repeated exposure**

Not classified based on available information.

### **Components:**

#### **Tafluprost:**

Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### **Components:**

#### **Tafluprost:**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

Species	: Rat
LOAEL	: 0.01 mg/kg
Application Route	: Intravenous
Exposure time	: 6 Months
Target Organs	: Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen

Species	: Dog
NOAEL	: 0.0001 mg/kg
LOAEL	: 0.001 mg/kg
Application Route	: Intravenous
Exposure time	: 39 Weeks
Target Organs	: Cardio-vascular system, Eye
Symptoms	: Dilatation of the pupil

### **Glycerine:**

Species	: Rat
NOAEL	: 0.167 mg/l
LOAEL	: 0.622 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 13 Weeks

Species	: Rat
NOAEL	: 8,000 - 10,000 mg/kg
Application Route	: Ingestion
Exposure time	: 2 yr

Species	: Rabbit
NOAEL	: 5,040 mg/kg
Application Route	: Skin contact
Exposure time	: 45 Weeks

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

#### **Tafluprost:**

Eye contact	: Symptoms: dryness of the eyes, Blurred vision
-------------	---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### **Components:**

#### **Glycerine:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l Exposure time: 96 h
------------------	--

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l  
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

### 12.2 Persistence and degradability

#### Components:

##### **Glycerine:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 92 %  
Exposure time: 30 d  
Method: OECD Test Guideline 301D

### 12.3 Bioaccumulative potential

#### Components:

##### **Tafluprost:**

Partition coefficient: n-octanol/water : log Pow: 4.5

##### **Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.75

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

Contaminated packaging : According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

#### 14.1 UN number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

#### 14.4 Packing group

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA (Cargo)	: Not regulated as a dangerous good
IATA (Passenger)	: Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	: Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	: Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	: Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	: Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	: Not applicable
The Control of Explosives Precursors and Poisons Regulations (Poisons Act, as amended)	
This product is regulated by the Poisons Act 1972 (as amended). All suspicious transactions, and significant disappearances and thefts must be reported.	Hydrochloric acid (Schedule 1A Part 1)
Control of Major Accident Hazards Regulations 2015 (COMAH)	
Not applicable	

### The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

### Full text of H-Statements

H302	: Harmful if swallowed.
H319	: Causes serious eye irritation.
H360D	: May damage the unborn child.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H413	: May cause long lasting harmful effects to aquatic life.

### Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure
GB EH40	: UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	: Long-term exposure limit (8-hour TWA reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
6.1	14.04.2025	9372636-00010	Date of first issue: 27.08.2021

---

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN